Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsRaw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Outlook Therapeutics (OTLK) Common Equity (2016 - 2025)

Historic Common Equity for Outlook Therapeutics (OTLK) over the last 8 years, with Q4 2025 value amounting to -$38.5 million.

  • Outlook Therapeutics' Common Equity rose 2334.63% to -$38.5 million in Q4 2025 from the same period last year, while for Dec 2025 it was -$38.5 million, marking a year-over-year increase of 2334.63%. This contributed to the annual value of -$32.2 million for FY2025, which is N/A changed from last year.
  • As of Q4 2025, Outlook Therapeutics' Common Equity stood at -$38.5 million, which was up 2334.63% from -$32.2 million recorded in Q3 2025.
  • In the past 5 years, Outlook Therapeutics' Common Equity registered a high of -$32.2 million during Q3 2025, and its lowest value of -$50.3 million during Q4 2024.